Medication Guides
Confirmed accurate: August 6, 2026

Lantus Savings Card 2026: $35 Guide, the Valyou Program, and What Replaced Semglee

Lantus — available, pen intermittent
Semglee — discontinued 12/31/25
Rezvoglar — interchangeable
Basaglar — needs new script
Generic glargine — available
Evan Brown
Written by Evan Brown
Prescription Savings Researcher
Dr Megan Harris Medically Reviewed by Dr. Megan Harris, MD
Why trust this guide: We pulled current terms directly from Sanofi's own Lantus copay and Valyou program pages, confirmed Sanofi Patient Connection's published eligibility rules, and cross-checked the Semglee discontinuation against ASHP's drug shortage tracker. Program terms are set by Sanofi and can change — always confirm current details at enrollment.
Quick Answer

There are actually two different Lantus savings programs, and mixing them up is the most common mistake. The Lantus Copay Savings Card is for commercially insured patients and caps your cost at $35 or less per 30-day supply. The separate Insulins Valyou Savings Program is for uninsured patients, or insured patients paying cash, and also caps Lantus at $35 per 30-day supply — but only if you fill all your Sanofi insulin prescriptions together each month. Neither program works with Medicare or Medicaid.

The other thing worth knowing right now: Semglee, the interchangeable Lantus biosimilar, was discontinued on December 31, 2025, which pushed a lot of demand back onto brand Lantus and strained supply of the SoloStar pen specifically. Rezvoglar is the closest replacement — it's also FDA-designated interchangeable with Lantus, so a pharmacist can generally substitute it the same way Semglee used to work.

Key Takeaways

  • Commercially insured: $35 or less per 30-day supply through the Lantus Copay Savings Card, up to 10 packs per fill.
  • Uninsured/cash-pay: $35 per 30-day supply through the separate Insulins Valyou Savings Program — must fill all Sanofi insulins together to get the combined cap.
  • Very low income: Sanofi Patient Connection can provide Lantus completely free if you're at or below 400% of the Federal Poverty Level and lack coverage.
  • Not eligible for either Sanofi card: Medicare, Medicaid, VA, DOD, or TRICARE — Medicare Part D enrollees get a separate $35/month cap under the Inflation Reduction Act instead.
  • Semglee is gone. Discontinued December 31, 2025. Rezvoglar is the current FDA-designated interchangeable replacement; Basaglar and generic glargine are alternatives that need a new prescription.

Lantus (insulin glargine) has been a backbone basal insulin for people with type 1 and type 2 diabetes for years, and Sanofi's savings programs are genuinely generous compared to where insulin pricing used to sit. But "the Lantus savings card" isn't one single thing — it's two separate programs with different rules depending on your insurance status, plus a third option for patients who need it completely free. On top of that, the insulin glargine market itself shifted in a real way at the end of 2025 when a major biosimilar disappeared. This guide sorts out all of it: which program applies to you, what it actually costs, and what to do if your usual product is hard to find at the pharmacy.

1. What Is the Lantus Savings Card?

Sanofi runs two distinct savings programs for Lantus, and confusing them is the single most common mistake patients make when searching for "the Lantus savings card."

Sanofi's two Lantus programs, side by side
ProgramWho It's ForWhat You Pay
Lantus Copay Savings CardCommercially insured patients$35 or less per 30-day supply, up to 10 packs/fill
Insulins Valyou Savings ProgramUninsured, or insured patients paying cash$35 per 30-day supply of one or combined Sanofi insulins

Both programs exclude Medicare, Medicaid, VA, DOD, TRICARE, and similar government programs. Both are administered directly by Sanofi and require registration before your first discounted fill — see the official terms at lantus.com/sign-up-for-savings.

2. Big Update: Semglee Is Gone — What Replaces It

This is the development that's reshaped the entire insulin glargine landscape heading into the second half of 2026. Biocon discontinued Semglee — its vials and pens — on December 31, 2025. Semglee mattered because it was the first FDA-designated interchangeable biosimilar insulin, meaning a pharmacist could substitute it for Lantus automatically, the same way a generic gets swapped in without a new prescription.

What happened next: millions of patients who were stable on Semglee had to shift back to brand Lantus or another glargine product almost overnight. That demand shock is the main reason Sanofi has acknowledged intermittent supply pressure on the Lantus SoloStar pen specifically through 2026 — vials have generally stayed easier to find than pens.

The practical question for most patients is: what replaces Semglee's convenience? The answer is Rezvoglar, made by Eli Lilly. It's also FDA-designated interchangeable with Lantus, so in most cases a pharmacist can substitute it the same way Semglee worked, without going back to your prescriber first — though it's worth confirming with your specific pharmacist, since interchangeable status doesn't guarantee every pharmacy stocks it or that every state applies substitution rules identically.

  • Rezvoglar (Lilly): interchangeable — can typically be substituted at the pharmacy like Semglee was.
  • Basaglar (Lilly): a related follow-on insulin glargine, but not interchangeable — needs a new prescription from your doctor.
  • Generic (unbranded) insulin glargine: available from several manufacturers, regional availability varies.
  • Toujeo (Sanofi): also insulin glargine, but a different concentration (U-300 vs. Lantus's U-100) — not a unit-for-unit swap.

See our dedicated Lantus shortage guide for real-time availability tips and pharmacy-finding tools if you're currently struggling to fill a SoloStar pen prescription.

3. Is There a Lantus Coupon or Manufacturer Coupon?

Sanofi doesn't issue a traditional printable "coupon" for Lantus. When people search for a Lantus coupon or manufacturer coupon, they're describing the same benefit as the two programs above — they function like a coupon at checkout, but the terms depend on your insurance status rather than a flat discount code.

Bottom line: "Lantus coupon" almost always means either the Copay Savings Card or the Valyou Savings Program described in this guide. A free discount card like GoodRx or SingleCare is a separate, independent option that can sometimes match or beat Sanofi's own pricing — typically in the $35–$100 range per fill — but it can't be combined with Sanofi's programs on the same transaction. See our GoodRx vs. Inside Rx comparison for how these independent cards stack up generally.

4. Lantus Copay Card: For Commercially Insured Patients

If you have employer-sponsored or ACA marketplace insurance, the Copay Savings Card can bring your Lantus cost down to $35 or less for a 30-day supply, up to 10 packs per fill, with one fill allowed every 30 days.

  • Federal Employees Health Benefits (FEHB) plans are treated as eligible — FEHB is not considered a government program for this specific offer.
  • ACA Health Insurance Exchange plans are eligible too.
  • Not valid if your prescription is billed to Medicare, Medicaid, VA, DOD, TRICARE, or a similar state pharmaceutical program.

Watch for copay accumulator programs. Some commercial plans apply Sanofi's contribution to your bill without counting it toward your deductible or annual out-of-pocket maximum. Ask your insurer directly whether your plan uses a copay accumulator or maximizer for brand-name drugs.

5. Lantus Savings Card Without Insurance (Valyou)

Uninsured patients — and insured patients who choose to pay cash instead of running Lantus through their benefit — use the Insulins Valyou Savings Program instead of the Copay Card. It caps the price at $35 per 30-day supply of any one or combination of Sanofi insulins.

The fine print that trips people up: to get the combined $35 cap, you must fill all of your Sanofi insulin prescriptions together, at the same time, each month. If you take only Lantus, this is simple. If you take Lantus plus another Sanofi insulin, filling them on different days can affect whether the combined cap applies.

Without any program, a 10 mL vial of Lantus typically runs somewhere between $80 and $360 depending on the pharmacy, following Sanofi's 78% list price reduction that took effect in 2024 — pen formats can run somewhat higher. The Valyou program brings either format down to $35 for a 30-day supply.

6. Free Lantus: Sanofi Patient Connection

For patients who can't manage even $35 a month, Sanofi Patient Connection can provide Lantus at no cost if you meet its eligibility rules:

  • U.S. or U.S. territory resident, under the care of a licensed prescriber.
  • No insurance coverage or access to Lantus through your existing plan.
  • If you might qualify for Medicaid, you'll generally need to show documentation of a Medicaid denial first.
  • Household income at or below 400% of the Federal Poverty Level.

Our Sanofi Patient Connection guide walks through the full application in detail, and our broader patient assistance program directory covers comparable programs from other manufacturers if you're managing more than one prescription.

7. Lantus Cost: List Price vs. Card vs. Alternatives

Approximate monthly cost by path (August 2026)
OptionTypical Monthly CostBest For
Lantus, no assistance~$80–$360 (vial), often more for pensNot recommended if any program applies
Lantus + Copay Card, commercial insurance$35 or lessCommercially insured patients
Lantus + Valyou Program, uninsured$35Uninsured or cash-pay patients
Free discount coupon (GoodRx/SingleCare)~$35–$100Comparison shopping against Sanofi's own terms
Sanofi Patient Connection$0Uninsured patients at or below 400% FPL
Medicare Part D$35 (IRA cap)Medicare enrollees

See our Medicare Part D insulin cap guide for how the Inflation Reduction Act's $35/month protection actually works at the pharmacy counter, and our Extra Help (LIS) guide if your income is limited and you're on Medicare.

8. Eligibility & Who Qualifies

Commercial Insurance

Copay Savings Card, $35 cap.

Uninsured / Cash-Pay

Valyou Program, $35 cap.

Medicare

Excluded — Part D's own $35 cap applies instead.

Medicaid

Excluded — state formulary rules apply instead.

9. Income Limits Compared

Income limit comparison
ProgramIncome LimitInsurance Requirement
Lantus Copay Savings CardNoneCommercial insurance required
Insulins Valyou Savings ProgramNoneUninsured or paying cash
Sanofi Patient Connection≤400% of Federal Poverty LevelUninsured or no access via existing plan
Medicare Extra Help (LIS)Federal thresholds updated annuallyEnrolled in Medicare Part D

10. Covered Medications Compared

Insulin glargine family status, August 2026
ProductManufacturerStatusSubstitution
LantusSanofiAvailable (vial); SoloStar pen intermittentBrand — Copay Card / Valyou apply
SemgleeBiocon/ViatrisDiscontinued 12/31/2025No longer an option
RezvoglarEli LillyAvailableInterchangeable — pharmacist can typically substitute
BasaglarEli LillyAvailableNot interchangeable — needs new prescription
Generic insulin glargineMultipleAvailable, regional variabilityCash-pay alternative
ToujeoSanofiAvailableDifferent concentration (U-300) — not unit-for-unit

If your prescriber is considering a switch to a Novo Nordisk basal insulin like Tresiba instead of another glargine product, that manufacturer runs its own $35/month program through NovoCare, separate from anything Sanofi offers. Our manufacturer savings card guides cover the Lilly-run programs for Basaglar and Rezvoglar in more detail, including the Lilly Insulin Value Program's own $35 structure through Lilly Cares.

11. How to Enroll Step-by-Step

1

Identify your insurance status

Commercial insurance points you to the Copay Savings Card. Uninsured or cash-pay points you to the Valyou Savings Program. Neither works with Medicare or Medicaid.

2

Register at lantus.com

Sign up for the correct program before your pharmacy visit. Registration takes only a few minutes and confirms your eligibility upfront.

3

If you take multiple Sanofi insulins, plan your fills together

Under Valyou, fill all your Sanofi insulin prescriptions on the same visit each month to make sure the combined $35 cap applies correctly.

4

Present your card at the pharmacy

Hand over your registered card along with your prescription. Most major pharmacy chains and many independents are familiar with both Sanofi programs.

5

If cost is still a barrier, apply to Sanofi Patient Connection

Have your prescriber help complete the application if your income falls at or below 400% of the Federal Poverty Level and you lack coverage.

12. Approval Timelines

What to expect and when
ProgramTypical Timeline
Copay Savings CardImmediate once registered
Insulins Valyou Savings ProgramImmediate once registered
Sanofi Patient ConnectionTypically 2–4 weeks with a complete application
Prior authorization, if your plan requires itUsually 3–14 business days, longer if appealed

If your Lantus prescription is stuck in a coverage review, our prior authorization guide covers documentation that typically speeds up approval.

13. Renewal Process

Sanofi periodically republishes the terms of both the Copay Savings Card and the Valyou Savings Program. Set a reminder near the start of each year to confirm your registration is still active and the $35 figure hasn't changed. If your pharmacy suddenly quotes a higher price, that's usually the first sign a renewal or re-registration is needed. Sanofi Patient Connection enrollees should expect a periodic income and coverage recheck as well.

14. Decision Path: Which Program Fits You?

Do you have commercial insurance for Lantus?
Yes — Insured
Register for the Copay Savings Card.
Ask about copay accumulator programs before you rely on the discount for your deductible.
Result: as low as $35 or less per 30-day supply.
No — Uninsured / Cash-Pay
Register for the Insulins Valyou Savings Program instead.
Still too much? Apply to Sanofi Patient Connection if your income is at or below 400% FPL.
Result: $35 per 30-day supply, or $0 if Patient Connection approves you.

Separate question either way: if you can't find your usual Lantus product in stock, that's a supply issue, not a savings issue — see the Semglee update above and our shortage guide for what to ask your pharmacist about switching to Rezvoglar or generic glargine.

15. Real Patient Examples

How three different patients approached their Lantus cost
PatientSituationBest PathResult
Angela, 58Employer insurance, high-deductible planCopay Savings Card$35/fill, well under her deductible copay
Tomas, 41Recently uninsured after a job changeInsulins Valyou Program$35/month instead of ~$300 cash price
Renee, 66Fixed income, no insurance, below 400% FPLSanofi Patient ConnectionFree Lantus after a ~3-week approval

16. Pros and Cons

Pros

  • No income requirement for either the Copay Card or Valyou Program
  • Works for both insured and uninsured patients at the same $35 target price
  • Free option available through Sanofi Patient Connection for very low income
  • Instant activation for both main programs — no waiting period

Cons

  • Two separate programs with different rules is genuinely confusing
  • Excludes Medicare and Medicaid entirely
  • Valyou's combined cap requires filling all Sanofi insulins together
  • SoloStar pen supply has been intermittent since Semglee's discontinuation

17. Common Mistakes

Assuming there's just one "Lantus savings card."
Reality: there are two — the Copay Card for insured patients and the Valyou Program for cash-pay patients.
Filling multiple Sanofi insulins on different days and expecting the combined $35 Valyou cap anyway.
Reality: Valyou requires filling all your Sanofi insulin prescriptions together each month.
Trying to use either Sanofi card while enrolled in Medicare or Medicaid.
Reality: both programs exclude government insurance; Medicare Part D has its own separate $35 cap.
Assuming Semglee is just temporarily out of stock.
Reality: Semglee was permanently discontinued on December 31, 2025.
Expecting a pharmacist to swap Lantus for Basaglar automatically.
Reality: Basaglar isn't interchangeable — you need a new prescription. Rezvoglar is the one that typically can be substituted.
Stacking a GoodRx coupon with a Sanofi program on the same fill.
Reality: pharmacies apply one discount per transaction — compare and pick the lower price instead.

Frequently Asked Questions

It's Sanofi's manufacturer copay program for Lantus (insulin glargine). Eligible commercially insured patients pay no more than $35 for a 30-day supply, up to 10 packs per fill. It is a separate program from the Valyou Savings Program, which is Sanofi's cash-pay option for uninsured patients.

Sanofi does not issue a traditional printable coupon for Lantus. The Lantus Copay Savings Card and the Insulins Valyou Savings Program both function like a coupon at the pharmacy, and together they cap most patients' cost at $35 or less per 30-day supply regardless of insurance status.

The Copay Savings Card is for commercially insured patients and caps their cost at $35 per 30-day supply on top of their insurance. The Insulins Valyou Savings Program is for uninsured patients, or insured patients choosing to pay cash outside their benefit, and caps the price at $35 per 30-day supply of any one or combination of Sanofi insulins, provided all Sanofi insulin prescriptions are filled together each month.

Without any savings program, a 10 mL vial of Lantus typically costs somewhere between $80 and $360 depending on the pharmacy, following Sanofi's 78% list price reduction that took effect in 2024. With the Insulins Valyou Savings Program, uninsured patients can bring that down to $35 for a 30-day supply.

Possibly. Sanofi Patient Connection provides certain Sanofi medications, including Lantus, at no cost to eligible patients. You generally need to be a U.S. or territory resident under a licensed prescriber's care, have no insurance coverage or access to Lantus through your plan (or provide documentation of a Medicaid denial), and have household income at or below 400% of the Federal Poverty Level.

No. Both the Lantus Copay Savings Card and the Insulins Valyou Savings Program exclude prescriptions billed to Medicare, Medicaid, VA, DOD, TRICARE, or similar government programs. Medicare Part D enrollees are instead protected by the Inflation Reduction Act's separate $35-per-month insulin copay cap.

Biocon discontinued Semglee vials and pens on December 31, 2025. Semglee had been FDA-designated as interchangeable with Lantus, meaning pharmacists could substitute it automatically. Its discontinuation shifted a large number of patients back onto brand Lantus and other insulin glargine products, contributing to intermittent supply pressure on the Lantus SoloStar pen through 2026.

Rezvoglar (Eli Lilly) contains the same active ingredient, insulin glargine, and is FDA-designated as interchangeable with Lantus, similar to how Semglee previously worked. That designation generally allows a pharmacist to substitute it for Lantus without a new prescription, though you should confirm with your specific pharmacist and prescriber.

Many patients do, especially during supply disruptions. Basaglar is a follow-on insulin glargine product but is not designated interchangeable, so it requires a new prescription rather than an automatic pharmacy substitution. Unbranded generic insulin glargine is also available from several manufacturers and can be a lower-cost cash option, subject to regional availability.

Brand Lantus is not in a formal FDA-listed shortage, but Sanofi has acknowledged intermittent supply pressure on the SoloStar pen specifically, driven largely by demand that shifted over from Semglee after its discontinuation in December 2025. Lantus vials have generally remained easier to find than the pen format.

Sanofi periodically renews and republishes the terms of both the Copay Savings Card and the Insulins Valyou Savings Program. Reverify your card's current terms at least once a year, and immediately if your pharmacy stops applying the expected discount.

Generally no — pharmacies apply one discount per transaction. Compare the price under Sanofi's own programs against a free GoodRx or SingleCare coupon at your specific pharmacy, since either one can occasionally come out lower depending on location.

Under the Insulins Valyou Savings Program, the $35 cap applies to any one or combination of Sanofi insulins, but only if you fill all of your Sanofi insulin prescriptions together at the same time each month. Filling them separately can affect whether the combined cap applies.

If you manage more than insulin — a GLP-1, an SGLT2 inhibitor, or another chronic prescription — the same pattern of manufacturer copay cards and income-based patient assistance shows up across most drug makers. Eli Lilly runs its programs through Eli Lilly and Lilly Cares; Novo Nordisk runs its own through Novo Nordisk and NovoCare. Our manufacturer savings card guides break each of these down the same way this page breaks down Lantus.

For background on interchangeable biosimilar designations and drug shortages generally, the FDA's drug database is the primary source. For Medicare-specific insulin pricing rules, see Medicare.gov and CMS. If none of Sanofi's programs fit your situation, NeedyMeds and BenefitsCheckUp can help you screen for other state or nonprofit assistance.

Editorial Policy: This guide reflects Sanofi's published Lantus Copay Savings Card and Insulins Valyou Savings Program terms, Sanofi Patient Connection's eligibility rules, and the confirmed Semglee discontinuation as of August 6, 2026. Program eligibility, pricing, and product availability are controlled by Sanofi and are subject to change without notice. This is educational content, not medical or financial advice — talk to your prescriber before switching between insulin glargine products.

Evan Brown
About the Author
Evan Brown — Prescription Savings Researcher

Evan Brown is a medical content researcher who specializes in translating manufacturer savings programs and insurance rules into clear, actionable guidance for patients.

View Full Profile →
Dr. Megan Harris, MD
Medical Review
Dr. Megan Harris, MD

Dr. Megan Harris, MD reviews health content for medical accuracy, checking program eligibility and drug information against current manufacturer and FDA guidance.

View Full Profile →

Contact Refill Relay